At the 20th Congress of the European Hematology Association (EHA), Claire Harrison, MD, DM, FRCP, FRCPath, of Guy’s and St Thomas’ NHS Foundation Trust, London, UK, discusses the final results of the Evaluation of Xagrid® Efficacy and Long-term Safety (EXELS) trial. EXELS is an observational phase 4 trial that compared safety, pregnancy outcomes, and efficacy, measured by incidence of thrombohaemorrhagic events and platelet reduction, of anagrelide compared with other cytoreductive therapies in high-risk patients with essential thrombocythemia.
Get great new content delivered to your inboxSign up
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest Hemonc news and updates